Could a pill replace IVF shots? new study tests oral drug

NCT ID NCT05994378

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tested whether an oral tablet called SHR7280 works as well as the standard injection (ganirelix) for preventing early ovulation in women undergoing IVF. The study involved 317 infertile women aged 20-39. If effective, the pill could offer a more convenient option, but it is not a cure for infertility—it is a tool to improve the success of IVF procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SHR7280 (oral tablet) and ganirelix acetate (injection)

What this could lead to

If successful, this could offer a more convenient oral alternative to daily injections for women undergoing IVF, potentially reducing discomfort and simplifying treatment.

What could go wrong

This is a non-inferiority trial, meaning it aims to show SHR7280 is not worse than the existing injection, not necessarily better. The results may not apply to all infertility patients, and oral medications can have different side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFERTILE FEMALE SUBJECTS UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION TO SUPPRESS PREMATURE LH SURGE AND PREVENT EARLY OVULATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

female infertility infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191, China